2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
- PMID: 16239238
- DOI: 10.1093/annonc/mdi961
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
Similar articles
-
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.Ann Oncol. 2017 Nov 1;28(suppl_8):viii30-viii35. doi: 10.1093/annonc/mdx449. Ann Oncol. 2017. PMID: 29232472 Free PMC article. Review.
-
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.Int J Gynecol Cancer. 2011 May;21(4):750-5. doi: 10.1097/IGC.0b013e31821b2568. Int J Gynecol Cancer. 2011. PMID: 21543936 Review.
-
Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S61-6. doi: 10.1097/IGC.0000000000000261. Int J Gynecol Cancer. 2014. PMID: 25341583 Free PMC article. Review.
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.Lancet Oncol. 2022 Aug;23(8):e374-e384. doi: 10.1016/S1470-2045(22)00139-5. Lancet Oncol. 2022. PMID: 35901833 Free PMC article. Review.
-
The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer.Int J Gynecol Cancer. 2011 May;21(4):746-9. doi: 10.1097/IGC.0b013e31821bb446. Int J Gynecol Cancer. 2011. PMID: 21543935
Cited by
-
A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer.J Gynecol Oncol. 2024 Nov;35(6):e76. doi: 10.3802/jgo.2024.35.e76. Epub 2024 Mar 26. J Gynecol Oncol. 2024. PMID: 38576344 Free PMC article.
-
Lymphadenectomy in clinically early epithelial ovarian cancer and survival analysis (LILAC): a Gynecologic Oncology Research Investigators Collaboration (GORILLA-3002) retrospective study.J Gynecol Oncol. 2024 Jul;35(4):e75. doi: 10.3802/jgo.2024.35.e75. Epub 2024 Mar 12. J Gynecol Oncol. 2024. PMID: 38497109 Free PMC article.
-
Exploring the Potential Role of Upper Abdominal Peritonectomy in Advanced Ovarian Cancer Cytoreductive Surgery Using Explainable Artificial Intelligence.Cancers (Basel). 2023 Nov 13;15(22):5386. doi: 10.3390/cancers15225386. Cancers (Basel). 2023. PMID: 38001646 Free PMC article.
-
High density of CXCL12-positive immune cell infiltration predicts chemosensitivity and recurrence-free survival in ovarian carcinoma.J Cancer Res Clin Oncol. 2023 Dec;149(20):17943-17955. doi: 10.1007/s00432-023-05466-8. Epub 2023 Nov 15. J Cancer Res Clin Oncol. 2023. PMID: 37966614 Free PMC article.
-
Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and overall survival.J Gynecol Oncol. 2023 Nov;34(6):e82. doi: 10.3802/jgo.2023.34.e82. Epub 2023 Sep 5. J Gynecol Oncol. 2023. PMID: 37743060 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical